Centiva Capital LP Has $1 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Centiva Capital LP lessened its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 48.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,144 shares of the medical equipment provider's stock after selling 8,689 shares during the period. Centiva Capital LP's holdings in Lantheus were worth $1,004,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 208 shares in the last quarter. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC acquired a new stake in shares of Lantheus during the second quarter worth about $47,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus during the 3rd quarter valued at about $51,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on LNTH. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial restated a "buy" rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities decreased their price objective on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday, November 7th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $130.00.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.32 during trading hours on Friday, hitting $89.02. 551,649 shares of the company traded hands, compared to its average volume of 1,016,929. The stock has a market capitalization of $6.19 billion, a price-to-earnings ratio of 14.87 and a beta of 0.45. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The business's 50-day moving average is $99.75 and its 200-day moving average is $97.38.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.